stockrow
Friday 6 November 2026
Export RCUS’s income statement to Excel — free account
Arcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
18.36
0.67
+3.79%
Follow RCUS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.36 | 11.48 | 33.23 | 32.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.33) | (19.63) | (32.67) | (37.39) | |
P/B ratio |
4.06 | 5.17 | 8.38 | 9.19 | |
Price to Tangible BV |
4.06 | 5.17 | 8.38 | 9.19 | |
EV/Sales |
6.79 | 8.42 | 28.09 | 27.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.48) | (4.07) | (6.93) | (5.94) | |
EV/FCF |
(3.47) | (4.05) | (6.90) | (5.92) | |
Quick Ratio |
4.29 | 3.95 | 3.73 | 3.26 | |
Current Ratio |
4.36 | 4.04 | 3.82 | 3.34 | |
Net Debt/EBITDA |
7.74 | 5.35 | 6.26 | 0.00 | |
Debt/Assets |
8.69% | 10.03% | 10.93% | 12.47% | |
Debt/Equity |
0.16 | 0.19 | 0.22 | 0.28 | |
Asset Turnover |
0.22 | 0.22 | 0.12 | 0.11 | |
Operating CF/Net income |
1.13 | 1.08 | 1.31 | 0.69 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Interest Coverage |
(57.00) | (44.67) | (32.00) | (43.67) | |
Research and Development Expense of Revenue |
366.67% | 717.65% | 275.61% | 1,300.00% | |
Selling, General and Administrative Expense of Revenue |
78.79% | 170.59% | 58.54% | 255.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
45.45% | 111.76% | 36.59% | 177.78% | |
Graham Net Nets |
0.20 | 0.14 | 0.08 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.85%) | (14.72%) | (12.65%) | (14.05%) | |
Free Cash Flow Yield |
(18.91%) | (18.09%) | (12.24%) | (14.19%) | |
Revenue per Share |
0.31 | 0.14 | 0.33 | 0.07 | |
Operating CF per Share |
(1.12) | (1.10) | (0.94) | (0.69) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.13) | (1.10) | (0.94) | (0.69) | |
Cash per Share |
9.13 | 6.56 | 5.57 | 4.95 | |
Shareholders Equity per Share |
5.88 | 4.18 | 3.68 | 2.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.88 | 4.18 | 3.68 | 2.81 | |
Free Cash Flow |
(121.00) | (138.00) | (119.00) | (88.00) | |
Working Capital |
776.00 | 635.00 | 558.00 | 465.00 | |
Capital Expenditures |
(1.00) | — | — | — | |
Net Current Asset Value |
499.00 | 371.00 | 296.00 | 204.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.50 | 9.00 | 25.50 | 14.50 | |
Average Payables |
30.00 | 30.50 | 31.50 | 43.00 | |
Average Assets |
1,144.50 | 1,076.50 | 999.50 | 896.00 | |
Average Common Equity |
558.00 | 527.50 | 506.50 | 397.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026